MedPath

Use of Adiana Tubal Occlusive Devices in Women With Hydrosalpinx Prior to In Vitro Fertilization

Phase 2
Conditions
Women Suffering From Unilateral or Bilateral Tubal Occlusion Due to Hydrosalpinx
Interventions
Device: Adiana placement
Registration Number
NCT01224080
Lead Sponsor
Reproductive Science Center
Brief Summary

A condition called hydrosalpinx occurs when one or both of the fallopian tubes is blocked with fluid. The fluid can leak into the tube and the uterus. The theory is that the fluid can harm the tubes and uterus making implantation more difficult or harm the embryo.

Detailed Description

Not available

Recruitment & Eligibility

Status
UNKNOWN
Sex
Female
Target Recruitment
10
Inclusion Criteria
  • Are willing to participate in this clinical study
  • Are able to comprehend and give informed consent for participation in this study
  • Have read, understood and signed an informed consent form
  • Have been unable to achieve pregnancy after trying for 1 year or greater and who have unilateral or bilateral hydrosalpinges as evidenced by laparoscopy or ultrasound or HSG
  • Have a Day #3 serum FSH<10, and Day #3 Estradiol<80
  • Recipient women undergoing a ovum donor cycle the donor must have a Day 3 serum FSH < 10 and Day 3 Estradiol < 80
  • Have an antral follicle count 10 or greater for both ovaries combined, if women using ovum donor (follicle count) will be based on eligible donor
  • Have a desire to receive treatment for their HS
  • Are willing to undergo a hysterosalpingogram (HSG) 3 months after ADIANA placement to confirm proximal tubal occlusion
Exclusion Criteria
  • Active or recent upper or lower pelvic infection
  • Known hypersensitivity to nickel as confirmed by skin test
  • Known allergy to contrast media
  • Pregnancy or suspected pregnancy
  • Delivery or termination of pregnancy less than six weeks prior to Adiana placements
  • BMI > 35
  • Abnormal pap smear (CIN2 or greater abnormality) within the past year
  • Pelvic malignancy
  • Severely retroverted uterus
  • Evidence of intrauterine abnormalities such as submucous fibroids, polyps, intrauterine adhesions or presence of a uterine septum
  • Abnormal Clomid Challenge Test or abnormal lab values on Day #3 serum FSH and Estradiol
  • Antral follicle count less than 10 (both ovaries combined)
  • Poor general or gynecologic health
  • Inability or refusal to provide informed consent

Study & Design

Study Type
INTERVENTIONAL
Study Design
SINGLE_GROUP
Arm && Interventions
GroupInterventionDescription
Adiana DeviceAdiana placementAll patients will undergo the Adiana Tubal Occlusion procedure. This procedure will be done in an office based setting and last approximately 1 hour.
Primary Outcome Measures
NameTimeMethod
Evaluate the success rate of proximal tubal occlusion with Adiana inserts in women with hydrosalpinx1 Year

Analysis of results will be performed on the intent-to-treat population defined as all subjects in whom device placement was attempted and on the per protocol population defined as all subjects who had successful placement of the Adiana occlusion device and were followed for a minimum of one year post HSG confirmation test.

Secondary Outcome Measures
NameTimeMethod
Observe implantation and clinical pregnancy rates post IVF1Year

Factors affecting the placement rate, tubal occlusion rate, and clinical pregnancy rate will be reviewed. This study employs an unblended, non randomized, single group design, in which subjects serve as their own controls. Because this feasibility study will enroll a maximum of ten (10) subjects, it is not designed with success/failure benchmarks, nor is it statistically powered to make any claims regarding effectiveness of hysteroscopic proximal tubal occlusion in women with hydrosalpinx who are planning to undergo IVF.

Trial Locations

Locations (1)

Reproductive Science Center

🇺🇸

San Ramon, California, United States

© Copyright 2025. All Rights Reserved by MedPath